Mark C. Kelley

6.8k citations

56 papers · 4.7k indexed · 2 hit papers · h-index 32

Oncology top 1%
Molecular Biology top 5%
Cancer Research top 1%
Radiology, Nuclear Medicine and Imaging top 1%
Immunology top 5%

Co-authors: Douglas B. Johnson Nora Hansen Edwin C. Glass Ingrid M. Meszoely Ingrid A. Mayer Jeffrey A. Sosman Armando E. Giuliano Philip I. Haigh
Topics: Cutaneous Melanoma Detection and Management (12 papers)Breast Cancer Treatment Studies (11 papers)MRI in cancer diagnosis (9 papers)
Cited by: Cancer Research Oncology Biophysics
Journals: Journal of Clinical Investigation Journal of Clinical Oncology Immunity
Partner nations: United States Australia Canada

In The Last Decade

Mark C. Kelley

54 papers receiving 4.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

2013 715 citations Hubing Shi, Willy Hugo et al. Cancer Discovery profile →
Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy

2019 540 citations Mark C. Kelley, Douglas B. Johnson et al. profile →

Peers

Countries citing papers authored by Mark C. Kelley

Since Specialization

Citations

This map shows the geographic impact of Mark C. Kelley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark C. Kelley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark C. Kelley more than expected).

Fields of papers citing papers by Mark C. Kelley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark C. Kelley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark C. Kelley. The network helps show where Mark C. Kelley may publish in the future.

Co-authorship network of co-authors of Mark C. Kelley

This figure shows the co-authorship network connecting the top 25 collaborators of Mark C. Kelley. A scholar is included among the top collaborators of Mark C. Kelley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark C. Kelley. Mark C. Kelley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Superparamagnetic iron oxide (SPIO) for axillary mapping in patients with ductal carcinoma in situ undergoing mastectomy: single-institution experience 2023 ·Breast Cancer Research and Treatment ·(unknown),Raeshell S. Sweeting,Ingrid M. Meszoely,(unknown),Rondi M. Kauffmann,Mark C. Kelley,Ana M. Grau,(unknown)	2
2	Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition 2020 ·Clinical Cancer Research ·Rebecca L. Shattuck-Brandt,Sheau‐Chiann Chen,Emily Murray,Christopher Andrew Johnson,(unknown),Jamye F. O’Neal,Rami N. Al‐Rohil,Caroline A. Nebhan,Vijaya Bharti,Kimberly B. Dahlman,Gregory D. Ayers,Chi Yan,Mark C. Kelley,Rondi M. Kauffmann,Mary Hooks,Ana M. Grau,Douglas B. Johnson,Anna E. Vilgelm,Ann Richmond	22
3	Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment 2020 ·Frontiers in Oncology ·Joe T. Sharick,Christine M. Walsh,Carley M. Sprackling,Cheri A. Pasch,(unknown),Karla Esbona,Alka Choudhary,Rebeca García‐Varela,Mark E. Burkard,Stephanie M. McGregor,Kristina A. Matkowskyj,Alexander A. Parikh,Ingrid M. Meszoely,Mark C. Kelley,Susan Tsai,Dustin A. Deming,Melissa C. Skala	96
4	MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21 2019 ·Science Translational Medicine ·Anna E. Vilgelm,Nabil Saleh,Rebecca L. Shattuck-Brandt,(unknown),(unknown),Sheau‐Chiann Chen,Christopher Andrew Johnson,Jinming Yang,(unknown),Chi Yan,Douglas B. Johnson,Rami N. Al‐Rohil,Ensar Halilovic,Rondi M. Kauffmann,Mark C. Kelley,Gregory D. Ayers,Ann Richmond	88
5	Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types 2018 ·Cancer Immunology Research ·Allison R. Greenplate,(unknown),(unknown),Deon B. Doxie,(unknown),Kirsten E. Diggins,Nalin Leelatian,Megan L. Rasmussen,Mark C. Kelley,Vivian Gama,Peter J. Siska,Jeffrey C. Rathmell,P. Brent Ferrell,Douglas B. Johnson,Jonathan M. Irish	21
6	Evaluating feasibility of an automated 3-dimensional scanner using Raman spectroscopy for intraoperative breast margin assessment 2017 ·Scientific Reports ·Giju Thomas,The‐Quyen Nguyen,Isaac J. Pence,(unknown),(unknown),Jennifer M. Giltnane,Melinda E. Sanders,Ana M. Grau,Ingrid M. Meszoely,Mary Hooks,Mark C. Kelley,Anita Mahadevan‐Jansen	52
7	PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses 2016 ·Clinical Cancer Research ·Jiqing Sai,Philip Owens,Sergey V. Novitskiy,Oriana E. Hawkins,Anna E. Vilgelm,Jinming Yang,Tammy Sobolik,Nicole Lavender,Andrew C. Johnson,Colt M. McClain,Gregory D. Ayers,Mark C. Kelley,Melinda E. Sanders,Ingrid A. Mayer,Harold L. Moses,Mark Boothby,Ann Richmond	89
8	Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models 2015 ·Clinical Cancer Research ·Yan Liu,Oriana E. Hawkins,Anna E. Vilgelm,Jeff S. Pawlikowski,Jeffrey Ecsedy,Jeffrey A. Sosman,Mark C. Kelley,Ann Richmond	20
9	Preliminary Results from a Prospective Trial of Preoperative Combined BRAF and MEK-Targeted Therapy in Advanced BRAF Mutation-Positive Melanoma 2015 ·Journal of the American College of Surgeons ·(unknown),(unknown),Kimberly B. Dahlman,Mark C. Kelley	23
10	Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells 2014 ·Cancer Research ·Anna E. Vilgelm,Jeff S. Pawlikowski,Yan Liu,Oriana E. Hawkins,Tyler A. Davis,(unknown),Kevin P. Weller,Linda W. Horton,Colt M. McClain,Gregory D. Ayers,David C. Turner,(unknown),Clinton F. Stewart,Jeffrey A. Sosman,Mark C. Kelley,Jeffrey Ecsedy,Jeffrey N. Johnston,Ann Richmond	82
11	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapybreakdown → 2013 ·Cancer Discovery ·Hubing Shi,Willy Hugo,Xiangju Kong,Aayoung Hong,Richard C. Koya,Gatien Moriceau,Thinle Chodon,Rongqing Guo,Douglas B. Johnson,Kimberly B. Dahlman,Mark C. Kelley,Richard Kefford,Bartosz Chmielowski,John A. Glaspy,Jeffrey A. Sosman,Nicolas van Baren,Georgina V. Long,Antoni Ribas,Roger S. Lo	715
12	RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors 2012 ·Clinical Cancer Research ·Yingjun Su,Anna E. Vilgelm,Mark C. Kelley,Oriana E. Hawkins,Yan Liu,Kelli L. Boyd,Sara Kantrow,Ryan Splittgerber,Sarah P. Short,Tammy Sobolik,Snjezana Zaja‐Milatovic,Kimberly B. Dahlman,Katayoun I. Amiri,Aixiang Jiang,Lu Wang,Yu Shyr,Darrin D. Stuart,Shawn Levy,Jeffrey A. Sosman,Ann Richmond	47
13	A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer 2011 ·Physics in Medicine and Biology ·Xia Li,E. Brian Welch,Lori R. Arlinghaus,A. Bapsi Chakravarthy,Lei Xu,Jaime Farley,Mary E. Loveless,Ingrid A. Mayer,Mark C. Kelley,Ingrid M. Meszoely,Julie A. Means‐Powell,Vandana G. Abramson,Ana M. Grau,John C. Gore,Thomas E. Yankeelov	54
14	Motion correction in diffusion‐weighted MRI of the breast at 3T 2011 ·Journal of Magnetic Resonance Imaging ·Lori R. Arlinghaus,E. Brian Welch,A. Bapsi Chakravarthy,Lei Xu,Jaime Farley,Vandana G. Abramson,Ana M. Grau,Mark C. Kelley,Ingrid A. Mayer,Julie A. Means‐Powell,Ingrid M. Meszoely,John C. Gore,Thomas E. Yankeelov	26
15	Statistical comparison of dynamic contrast‐enhanced MRI pharmacokinetic models in human breast cancer 2011 ·Magnetic Resonance in Medicine ·Xia Li,E. Brian Welch,A. Bapsi Chakravarthy,Lei Xu,Lori R. Arlinghaus,Jaime Farley,Ingrid A. Mayer,Mark C. Kelley,Ingrid M. Meszoely,Julie Means‐Powell,Vandana G. Abramson,Ana M. Grau,John C. Gore,Thomas E. Yankeelov	34
16	Identification of Markers of Taxane Sensitivity Using Proteomic and Genomic Analyses of Breast Tumors from Patients Receiving Neoadjuvant Paclitaxel and Radiation 2010 ·Clinical Cancer Research ·Joshua A. Bauer,A. Bapsi Chakravarthy,Jennifer M. Rosenbluth,Deming Mi,Erin H. Seeley,Nara De Matos Granja-Ingram,Maria G. Olivares,Mark C. Kelley,Ingrid A. Mayer,Ingrid M. Meszoely,Julie A. Means‐Powell,Kimberly N. Johnson,C. Jillian Tsai,Gregory D. Ayers,Melinda E. Sanders,Robert J. Schneider,Silvia C. Formenti,Richard M. Caprioli,Jennifer A. Pietenpol	142
17	A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets 2009 ·Clinical Cancer Research ·Yingjun Su,Katayoun I. Amiri,Linda W. Horton,Yingchun Yu,Gregory D. Ayers,Elizabeth Koehler,Mark C. Kelley,Igor Puzanov,Ann Richmond,Jeffrey A. Sosman	29
18	A nonrigid registration algorithm for longitudinal breast MR images and the analysis of breast tumor response 2009 ·Magnetic Resonance Imaging ·Xia Li,Benoît M. Dawant,E. Brian Welch,A. Bapsi Chakravarthy,(unknown),Ingrid A. Mayer,Mark C. Kelley,Ingrid M. Meszoely,John C. Gore,Thomas E. Yankeelov	49
19	Comparison of autofluorescence, diffuse reflectance, and Raman spectroscopy for breast tissue discrimination 2008 ·Journal of Biomedical Optics ·Shovan Kumar Majumder,Matthew D. Keller,Fouad Boulos,Mark C. Kelley,Anita Mahadevan‐Jansen	66
20	Lymphatic Mapping and Sentinel Lymphadenectomy After Preoperative Therapy for Stage II and III Breast Cancer 2003 ·Annals of Surgical Oncology ·Glen C. Balch,Suhail K. Mithani,(unknown),R. Daniel Beauchamp,Mark C. Kelley	76

About Mark C. Kelley

Mark C. Kelley is a scholar working on Oncology, Cancer Research and Biophysics, having authored 56 papers that have together received 4.7k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (12 papers), Breast Cancer Treatment Studies (11 papers) and MRI in cancer diagnosis (9 papers). The work is most often cited by research in Cancer Research (1.1k citations), Oncology (1.8k citations) and Biophysics (312 citations). Mark C. Kelley has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include Douglas B. Johnson, Nora Hansen, Edwin C. Glass, Ingrid M. Meszoely, Ingrid A. Mayer, Jeffrey A. Sosman, Armando E. Giuliano, Philip I. Haigh, Meghan B. Brennan and Wei Ye. Their work appears in journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Immunity.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact